VaccineNation Blog Weekly: Most read articles this week

vaccines, influenza, avian flu, investment

Welcome to the first edition of the VaccineNation Blog Weekly, where we highlight the top 5 articles read this week on our VaccineNation blog.  These top articles range from influenza vaccine developments to investment in immunization.  Let us know which one was your favourite, or that you found most useful.

1. Top 5 videos on influenza vaccine developments : Many groups worldwide are working in a wide-range of ongoing influenza research to find better ways to prevent, diagnose, and treat seasonal and pandemic influenza. Here you will find the top 5 video presentations from government and pharma companies delivered during the World Vaccine Congress, highlighting the latest research on influenza, regulatory landscape, vaccine coverage, immunological observations and more.

2. What you need to know: Vaccines in Emerging Markets : According to Decision Resources, "Emerging markets, particularly the BRIC markets, promise to be new engines for pharma growth in the face of faltering growth rates and growing challenges in the traditional stronghold major markets."  Here we look at several issues dealing with vaccine R&D, market potential, and partnerships in emerging markets.

3. F1000 Guest Post: Why we are safe, for now, from avian flu : We are delighted to present a guest post from Faculty of 1000 (F1000) on a paper that describes the actual molecular requirements for avian flu to adapt to a human host.  What would make avian influenza transmissible in humans? This is the question Yoshihiro Kawaoka and his team investigated in their much-anticipated study published in Nature earlier this year.

4. How to establish cost-effective vaccine manufacturing practices in Asia : Achieving cost efficiency is imperative in any manufacturing facility/line, and at World Vaccine Congress Asia 2012 last June, Dr I-Teh Tong, Director of Merck & Co., Inc, Pradip Patel, Vice President & Head Vaccine Manufacturing of Cadila Healthcare, Dr Mats Lundgren, Staff Scientist, R&D of GE Healthcare and Dr G S Reddy, Chief General Manager, Manufacturing of Indian Immunologicals discussed how to establish cost-effective vaccine manufacturing practices in Asia.

5. Investing in immunization : Throughout the past 40 years the question of cost and the economics of immunization has arisen.  Is it cost-effective? Who is paying for it?

Were there any others that you found particularly interesting that didn't make the list? Comment below and let us know!

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *